Publication date: Feb 08, 2025
Predictions regarding the on-going burden of SARS-CoV-2, and vaccine recommendations, require an understanding of infection-associated immune protection. We assessed whether early COVID-19 provided protection against Omicron infection. We enrolled a cohort of adults in Ontario, Canada, with COVID-19 prior to October 2020 (early infection, EI), and a matched cohort with COVID-19 testing and a negative PCR (non-EI). Participants completed baseline surveys then surveys every two weeks until January 2023. Multivariable Cox regression was used to assess factors associated with COVID-19 infection during the first 14 months of Omicron. Overall, 624 EI (70%) and 175 (77%) non-EI participants met criteria for analysis; 590 (95%) EI and 164 (94%) non-EI had received at least 2 COVID-19 vaccine doses prior to Omicron. Of 624 EI, 175 (28%) had one SARS-CoV-2 re-infection and 8 (1. 3%) had two, compared to 84 (48%) non-EI participants with one, 5 (2. 9%) with two and 1 (0. 6%) with 3 infections (P
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | infection |
| drug | DRUGBANK | Methionine |
| disease | MESH | re-infection |
| disease | MESH | Long Covid |
| disease | MESH | Infectious Diseases |
| pathway | REACTOME | Reproduction |
| disease | MESH | influenza |
| drug | DRUGBANK | Coenzyme M |
| disease | IDO | history |
| disease | MESH | death |
| drug | DRUGBANK | Aspartame |
| disease | MESH | asthma |
| pathway | KEGG | Asthma |
| disease | MESH | complications |
| disease | MESH | Diabetes mellitus |
| pathway | REACTOME | SARS-CoV-2 Infection |